Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

DFCI: 16-237 Ph1b PVX-410 in SMM (Multiple Myeloma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn how safe and comfortable PVX-410 in combination with CC-96241 (with and without lenalidomide) is for patients with smoldering multiple myeloma (SMM).
What is the Condition Being Studied?
Smoldering Multiple Myeloma Patients determined to be eligible, based on Screening assessments, will be enrolled in the study.

Who Can Participate in the Study?

Diagnosis of Smoldering Multiple Myeloma

Age Group

What is Involved?

First, we will ask for a blood sample to determine eligibility.

If still eligible you will be asked to:
-Take the study drug as directed
-Complete blood draws
-Give a bone marrow sample
-A body scan (MRI, CT, X-ray)

Study Details

Full Title
A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Citarinostat (CC-96241), a Histone Deacetylase Inhibitor (HDAC) with and without Lenalidomide for Patients with Smoldering Multiple Myeloma
Principal Investigator
Cell Therapy and Hematologic Malignancies Specialist
Protocol Number
IRB: PRO00100313
NCT: NCT02886065
Phase I
Contact the Duke Recruitment Innovation Center